Stocks Comparison
Pharma-Bio Serv vs SuperX AI Technology: revenue, profit, margins and growth compared
Pharma-Bio Serv brought in $9M of revenue in fiscal 2025, SuperX AI Technology $20.3M in fiscal 2026. Revenue changed by -5.3% at Pharma-Bio Serv and +1,878.6% at SuperX AI Technology on the year before, so SuperX AI Technology grew faster. Pharma-Bio Serv kept -1.1% of its revenue as net profit, SuperX AI Technology -527.7%. Free cash flow was -$221.5K at Pharma-Bio Serv and -$79.2M at SuperX AI Technology.
Side by side, latest fiscal year
| PBSV | SUPX | |
|---|---|---|
| Fiscal year ended | FY2025 (October 31, 2025) | FY2026 (June 30, 2026) |
| Revenue | $9M | $20.3M |
| Revenue growth | -5.3% | +1,878.6% |
| Net income | -$100.5K | -$107.3M |
| Net margin | -1.1% | -527.7% |
| Free cash flow | -$221.5K | -$79.2M |
| Free cash flow margin | -2.5% | -389.5% |
| Earnings per share (diluted) | -$0.00 | -$2.89 |
| Cash | $3.4M | $98.9M |
| Debt | n/a | $2.2M |
| Price to earnings | n/a | n/a |
| Market value | $11.5M | $222.6M |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #510 of 603 · Industrials | #479 of 603 · Industrials |
Over the years
Questions about Pharma-Bio Serv and SuperX AI Technology
Which is bigger by revenue, Pharma-Bio Serv or SuperX AI Technology?
SuperX AI Technology is bigger by revenue: $20.3M in fiscal 2026, against $9M for Pharma-Bio Serv in fiscal 2025.
Which keeps more of its revenue as profit, Pharma-Bio Serv or SuperX AI Technology?
Pharma-Bio Serv had a net margin of -1.1% in fiscal 2025; SuperX AI Technology had -527.7% in fiscal 2026.
Which grew revenue faster, Pharma-Bio Serv or SuperX AI Technology?
In their latest fiscal years revenue changed by -5.3% at Pharma-Bio Serv and +1,878.6% at SuperX AI Technology.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.